REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) - Dilution Analysis

10-Q filing | 13.1M shares outstanding

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into agreements to sell and issue shares of common stock, pre-funded warrants, Series G warrants, and Series H warrants in a registered public offering, with expected gross proceeds of $10.0 million. ($10.0M proceeds)

8-K filing: From October 1, 2025 through December 16, 2025, the Company issued a total of 19,794,000 shares of common stock upon the exercise of 19,794,000 common stock warrants, with exercise prices ranging between $0.335 and $0.50 per common stock warrant, and resulting in net proceeds of approximately $6.7 million; after giving effect to the warrant exercises, the Company had 116,849,932 shares of common stock outstanding as of December 16, 2025. ($6.7M proceeds)

10-Q filing | 115.1M shares outstanding

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into agreements to sell and issue 27,000,000 shares of common stock, Series E warrants exercisable for up to 27,000,000 shares of common stock, and Series F warrants exercisable for up to 27,000,000 shares of common stock in a registered public offering, for aggregate gross proceeds of $9,045,000. ($9.05M proceeds)

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into agreements to sell and issue 20,000,000 shares of common stock, Series C warrants exercisable for up to 20,000,000 shares, and Series D warrants exercisable for up to 20,000,000 shares in a registered public offering for gross proceeds of $10.0 million. ($10.0M proceeds)

10-Q filing | 48.6M shares outstanding

10-K filing | 46.7M shares outstanding

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into an underwriting agreement to offer, issue, and sell 12,000,000 shares of common stock, Series A warrants for 6,000,000 shares, and Series B warrants for 12,000,000 shares, for gross proceeds of $18.0 million. ($18.0M proceeds)

10-Q filing | 33.8M shares outstanding

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into an underwriting agreement for the offering, issuance, and sale of shares of common stock, pre-funded warrants, and warrants, with net proceeds expected to be approximately $4.1 million.

10-Q filing | 30.6M shares outstanding

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement to sell 1,898,734 shares of common stock and warrants to purchase 1,898,734 shares of common stock at a public offering price of $1.58 per share and $1.455 per warrant, with net proceeds expected to be approximately $3.0 million. ($3.0M proceeds)

10-Q filing | 29.9M shares outstanding

10-K filing | 27.9M shares outstanding

S-3 filing: Reviva Pharmaceuticals Holdings, Inc. files an S-3 form to register the offering and sale of up to $200,000,000 aggregate offering price of common stock, preferred stock, warrants, debt securities, subscription rights and units.

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement with healthcare-focused institutional investors and a Director Affiliate, to sell shares of common stock, pre-funded warrants, and warrants in a registered direct offering, with expected net proceeds of approximately $27.9 million. ($3.0M proceeds)

10-Q filing | 24.0M shares outstanding

10-Q filing | 22.4M shares outstanding

8-K filing: Reviva Pharmaceuticals reports $5.7 million in gross proceeds from warrant exercises during Q2 2023, including $4.74 million from Common Warrants and $0.915 million from Investor Warrants, resulting in 22,650,266 shares of Common Stock outstanding as of June 14, 2023. ($5.66M proceeds)

10-Q filing | 21.8M shares outstanding

10-K filing | 19.5M shares outstanding

POS AM filing: This prospectus relates to the resale from time to time, by the selling stockholders of (i) up to 3,359,684 shares of our common stock which the selling stockholders may acquire upon the exercise of outstanding warrants and (ii) up to 1,383,399 shares of Common Stock which the selling stockholders may acquire upon the exercise of outstanding pre-funded warrants.

10-Q filing | 19.3M shares outstanding

S-1 filing: This S-1 filing includes information on the resale of common stock issuable upon exercise of pre-funded warrants and common warrants issued in a registered direct offering and concurrent private placement.

8-K filing: Reviva Pharmaceuticals Holdings, Inc. entered into agreements to sell shares of common stock and warrants in a registered direct offering and a concurrent private placement, expecting to close on or about September 8, 2022. ($8.5M proceeds)

10-Q filing | 18.5M shares outstanding

10-Q filing | 15.1M shares outstanding

POS AM filing: This is a prospectus for the issuance of up to 6,881,313 shares of common stock upon warrant exercise and the offer and sale of up to 2,396,070 shares of common stock and up to 15,183 warrants by selling securityholders.

POS AM filing: This prospectus relates to the issuance of common stock upon the exercise of previously issued warrants.

10-K filing | 14.4M shares outstanding

S-3 filing: Reviva Pharmaceuticals Holdings, Inc. files an S-3 form to offer and sell up to $150,000,000 in aggregate of common stock, preferred stock, debt securities, subscription rights and units, and an additional offering of common stock up to $12,900,000 through a sales agreement with H.C. Wainwright & Co., LLC.

10-Q filing | 13.4M shares outstanding

10-Q filing | 13.4M shares outstanding

S-1/A filing: The company is offering 4,149,377 shares of common stock at a price determined by market conditions, with an indicated interest from Vedanta Associates, LP to purchase up to $2.0 million in shares.

10-Q filing | 9.2M shares outstanding

POS AM filing: This is a POS AM filing registering the issuance of common stock upon exercise of public warrants and the resale of common stock and private warrants by selling securityholders.

S-1/A filing: RVPH is offering 3,676,470 shares of common stock at a price of $5.44 per share.

S-1 filing: RVPH is offering shares of its common stock. The common stock is listed on the Nasdaq Capital Market under the symbol "RVPH". On April 15, 2021, the closing price of the common stock was $4.22 per share. Vedanta Associates, LP has indicated an interest in purchasing an aggregate of up to a maximum of $2.0 million in shares of common stock in this offering at the public offering price.

POS AM filing: This POS AM filing from 2021-03-25 registers the issuance of 6,325,000 shares of common stock upon exercise of public warrants, the resale of up to 3,443,417 shares of common stock (including shares from private warrants), and the resale of 556,313 private warrants by selling securityholders.

10-K filing | 9.2M shares outstanding

10-Q filing | 9.2M shares outstanding

S-1/A filing: Reviva Pharmaceuticals Holdings, Inc. is registering the issuance of 6,325,000 shares of common stock upon exercise of public warrants and the resale of 3,443,417 shares of common stock and 556,313 private warrants by selling securityholders.

S-1 filing: Reviva Pharmaceuticals Holdings, Inc. is registering the issuance of common stock underlying public warrants and the resale of common stock and private warrants by selling securityholders.

8-K filing: Reviva Pharmaceuticals Holdings, Inc. completed a business combination, issued 300,000 shares of common stock to Maxim Partners, LLC, and adopted an amended and restated certificate of incorporation and a new Code of Business Conduct and Ethics. ($2.11M proceeds)

8-K filing: Reviva Pharmaceuticals Holdings, Inc. consummated its business combination with Tenzing Acquisition Corp. on December 14, 2020, resulting in Reviva Pharmaceuticals Holdings, Inc. becoming the successor company. ($24.2M proceeds)

8-K filing: Tenzing Acquisition Corp. entered into a Non-Redemption Agreement with a Shareholder, issuing 55,050 shares of common stock and transferring 343,000 Private Placement Warrants and 197,500 Working Capital Warrants in exchange for the Shareholder's agreement not to redeem 367,000 Ordinary Shares.

8-K filing: Tenzing Acquisition Corp. entered into an additional backstop agreement with Reviva Pharmaceuticals, Inc. and an additional investor, pursuant to which such investor agrees to purchase 23,148 of the Company's ordinary shares in open market or private transactions, and the Company agreed to issue up to 2,314 shares of the Company in connection therewith.

8-K filing: Tenzing Acquisition Corp. entered into backstop agreements with Reviva Pharmaceuticals, Inc., and certain investors, where the investors agreed to purchase 417,518 of the Company's ordinary shares in open market or private transactions and hold such shares and in exchange, the Company agreed to issue to the Backstop Investors for each ten (10) Backstop Shares that they purchase one (1) share of common stock of the Company.

10-Q filing | 5.1M shares outstanding

10-Q filing | 5.1M shares outstanding

10-K filing | 7.7M shares outstanding

10-Q filing | 8.3M shares outstanding